<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Medications for pediatric obsessive-compulsive disorder</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Medications for pediatric obsessive-compulsive disorder</h1>
<div class="graphic"><div class="figure"><div class="ttl">Medications for pediatric obsessive-compulsive disorder</div><div class="cntnt"><table cellspacing="0"><colgroup width="10%"></colgroup><colgroup span="3" width="20%"></colgroup><colgroup width="30%"></colgroup> <tbody> <tr> <td class="subtitle1">Agent</td> <td class="subtitle1">Initial daily dose</td> <td class="subtitle1">Suggested dose titration based upon response</td> <td class="subtitle1">Maintenance daily dose range</td> <td class="subtitle1">Selected characteristics*</td> </tr> <tr> <td class="subtitle2_left" colspan="5">SSRIs*</td> </tr> <tr> <td class="indent1">Fluoxetine<sup>¶</sup></td> <td> <p>Children: 5 to 10 mg</p> Adolescents: 10 to 20 mg</td> <td>Increase daily dose by 5 to 10 mg (child) or 10 to 20 mg (adolescent) after 14 days or more</td> <td> <p>Pre-adolescent: 20 to 30 mg</p> Adolescent: 20 to 60 mg</td> <td> <ul> <li>Prolonged half-life</li> <li>Metabolized by and inhibits CYP2D6</li> </ul> </td> </tr> <tr> <td class="indent1">Fluvoxamine<sup>¶</sup></td> <td> <p>Children: 12.5 to 25 mg</p> Adolescents: 25 to 50 mg</td> <td>Increase daily dose by 25 mg (child) or 25 to 50 mg (adolescent) after 7 days or more</td> <td> <p>Pre-adolescent: 50 to 200 mg</p> Adolescent: 50 to 300 mg</td> <td> <ul> <li>Girls generally require lower maintenance doses than boys</li> <li>Give in divided doses with meals and bedtime to minimize side effects</li> <li>Metabolized by CYP1A2 and 2D6</li> <li>Inhibits CYP1A2 and 2C19</li> </ul> </td> </tr> <tr> <td class="indent1">Sertraline<sup>¶</sup></td> <td> <p>Children: 12.5 to 25 mg</p> Adolescents: 25 to 50 mg</td> <td>Increase daily dose by 25 (child) or 50 mg (adolescent) after 7 days or more</td> <td>25 to 200 mg</td> <td> <ul> <li>Diarrhea more frequent than other SSRIs</li> <li>Metabolized by CYP2D6</li> <li>Inhibits CYP2D6 with larger doses</li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="5">SSRI - potential alternate*</td> </tr> <tr> <td class="indent1">Paroxetine</td> <td> <p>Children age ≥7 years: 5 mg</p> Adolescents: 10 mg</td> <td>Increase daily dose by 10 mg after 7 to 14 days or more</td> <td>10 to 60 mg</td> <td> <ul> <li>Short half-life</li> <li>Mild anticholinergic side effects</li> <li>Metabolized by and inhibits CYP2D6</li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="5">TCA</td> </tr> <tr> <td class="indent1">Clomipramine<sup>¶</sup></td> <td>Children ≥10 years and adolescents: 25 mg</td> <td>Increase daily dose by 25 mg every 7 to 14 days or more</td> <td> <p>25 to 200 mg</p> Maximum: smaller of 200 mg or 3 mg/kg per day<sup>Δ</sup></td> <td> <ul> <li>Only TCA with demonstrated efficacy in pediatric OCD</li> <li>Cardiovascular screening including ECG recommended prior to initiating treatment</li> <li>Anticholinergic side effects may limit usefulness in children</li> <li>Drowsiness, irritability, and vomiting may be seen</li> <li>Give in divided doses with meals and at bedtime to minimize side effects</li> <li>Metabolized by CYPs 1A2, 2C19, and 3A4</li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="5">SGAs for SSRI augmentation</td> </tr> <tr> <td class="indent1">Risperidone</td> <td>0.25 mg</td> <td>Increase daily dose by 0.25 mg after 7 to 14 days or more</td> <td>Maximum: 1.5 to 2 mg</td> <td> <ul> <li>Metabolic adverse effects</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_lgnd">Clinicians should be aware of the potential for activating side effects of antidepressants in younger children and regulatory warnings of potential for an increased risk of suicidality in children. All doses shown are for oral administration.</div><div class="graphic_footnotes"><p>SSRI: selective serotonin reuptake inhibitor; TCA: tricyclic antidepressant; OCD: obsessive-compulsive disorder; ECG: electrocardiogram; SGA: second-generation antipsychotic.</p>
<p>* Common generally mild adverse effects of SSRIs seen in children treated for various anxiety disorders may include headache, anorexia, vomiting, sleep disturbance, and somnolence.</p>
<p>¶ Sertraline, fluoxetine, and fluvoxamine are approved for treatment of OCD in children age ≥6, 7, and 8 years respectively in the United States. Clomipramine is approved for treatment of OCD in children age ≥10 years in the United States.</p>
Δ Dose-related ECG changes have been reported in children and close monitoring is necessary with larger doses. According to the product information approved in the United States, doses &gt;2.5 mg/kg per day are not recommended in children.</div><div class="graphic_reference">Courtesy of authors with additional data from:
<ol>
<li>Katzman MA, Bleau P, Blier P, et al. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry 2014; 14:S1.</li>
<li>Rynn M, Puliafico A, Heleniak C, et al. Advances in pharmacotherapy for pediatric anxiety disorders. Depress Anxiety 2011; 28:76.</li>
<li>Martin A, Scahill L, Kratochvil C. Pediatric Psychopharmacology, Oxford University Press, New York 2010. p.480.</li>
</ol></div><div id="graphicVersion">Graphic 95416 Version 2.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
